SSgA Funds Management, Inc. recently announced the acquisition of new stake in OncoSec Medical Incorporated (NASDAQ:ONCS). The institutional investor has increased its shareholding in the Healthcare company by 1,166.95% to 25187.0 shares with purchase of 23199.0 shares. This fresh investment now brings its stake to 0.85% valued currently at $27202.0. In addition, Renaissance Technologies LLC raised its holdings by 21115.0 to 24179.0 shares.
With over 2.06 million OncoSec Medical Incorporated (ONCS) shares trading Tuesday and a closing price of $2.83 on the day, the dollar volume was approximately $5.82 million. The shares have shown a negative half year performance of -78.60% and its price on 03/14/23 lost nearly -2.08%. Currently, there are 2.97M common shares owned by the public and among those 2.05M shares have been available to trade.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Insiders at the company have transacted a total of 4 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 4 occasions, with total insider shares sold totaling 881 shares.
The top 3 mutual fund holders in OncoSec Medical Incorporated are Fidelity Extended Market Index Fu, Fidelity Nasdaq Composite Index E, and Fidelity Series Total Market Inde. Fidelity Extended Market Index Fu owns 7517.0 shares of the company’s stock, all valued at over $8118.0. Fidelity Nasdaq Composite Index E bought 12.0 shares to see its total holdings expand to 2000.0 shares valued at over $2160.0 and representing 0.07% of the shares outstanding. Fidelity Series Total Market Inde now owns shares totaling to 0.03% of the shares outstanding.
Shares of OncoSec Medical Incorporated (NASDAQ: ONCS) opened at $2.73, down -$0.16 from a prior closing price of $2.89. However, the script later moved the day high at 3.4800, down -2.08%. The company’s stock has a 5-day price change of 45.88% and 53.80% over the past three months. ONCS shares are trading 68.45% year to date (YTD), with the 12-month market performance down to -87.39% lower. It has a 12-month low price of $0.74 and touched a high of $31.90 over the same period. ONCS has an average intraday trading volume of 2.15 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 67.63%, 50.68%, and -69.63% respectively.
Institutional ownership of OncoSec Medical Incorporated (NASDAQ: ONCS) shares accounts for 8.40% of the company’s 2.97M shares outstanding. Mutual fund holders own 0.42%, while other institutional holders and individual stakeholders account for 4.96% and — respectively.
It has a market capitalization of $7.10M and a beta (3y monthly) value of 1.68. The earnings-per-share (ttm) stands at -$18.13. Price movements for the stock have been influenced by the stock’s volatility, which stands at 29.04% over the week and 24.13% over the month.
Analysts forecast that OncoSec Medical Incorporated (ONCS) will achieve an EPS of -$1.31 for the current quarter, -$0.77 for the next quarter and $0 for 2024. The lowest estimate earnings-per-share for the quarter is -$1.31 while analysts give the company a high EPS estimate of -$1.31. Comparatively, EPS for the current quarter was -$5.5 a year ago.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate OncoSec Medical Incorporated (ONCS) as a “Hold” at a consensus score of 3.00. Specifically, 0 Wall Street analysts polled rate the stock as a buy, while 1 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the ONCS, a number of firms have released research notes about the stock. BTIG Research stated their Buy rating for the stock in a research note on March 08, 2021, with the firm’s price target at $10. Dawson James coverage for the OncoSec Medical Incorporated (ONCS) stock in a research note released on July 27, 2020 offered a Buy rating with a price target of $10. H.C. Wainwright was of a view on November 07, 2018 that the stock is Neutral, while Piper Jaffray gave the stock Overweight rating on February 09, 2018, issuing a price target of $4. Rodman & Renshaw on their part issued Buy rating on July 21, 2016.
